Array CGH and DNA sequencing to personalize targeted treatment of metastatic breast cancer (MBC) patients (pts): A prospective multicentric trial (SAFIR01).
Fabrice André(Inserm), Hervé Bonnefoi, Anthony Gonçalvès(Centre National de la Recherche Scientifique), Magali Lacroix‐Triki(Université Paris-Saclay), Vladimir Lazar(Institut Gustave Roussy), David Gentien, Ivan Bièche(Centre National de la Recherche Scientifique), Thomas Bachelot(Centre Léon Bérard), Véronique Dièras(Institut Curie), Florence Dalenc(Institut Claudius Regaud), Frédéric Commo(Inserm), Mario Campone(Institut de Cancérologie de l'Ouest), Max Chaffanet(Centre National de la Recherche Scientifique), Marta Jimenez(UniCancer Group), Sylviane Olschwang(Inserm), Mónica Arnedos, Pascale A. Cohen(Lyon 1 Université), Qing Wang(Centre Léon Bérard), Marie‐Christine Mathieu(Université Paris-Saclay), Ludovic Lacroix(Centre National de la Recherche Scientifique)
Cited by 20
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k